Apimeds Pharmaceuticals US, Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APUS research report →
Companywww.apimedsus.com
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
- CEO
- Vinod Menon
- IPO
- 2025
- Employees
- 2
- HQ
- Hopewell, NJ, US
Price Chart
Valuation
- Market Cap
- $1.75M
- P/E
- -2.52
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -1074.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.02%
- ROIC
- -0.01%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-6,001,137 · -331.74%
- EPS
- $-0.55 · 54.17%
- Op Income
- $-11,912,562
- FCF YoY
- -1124.65%
Performance & Tape
- 52W High
- $40.31
- 52W Low
- $1.24
- 50D MA
- $5.39
- 200D MA
- $15.50
- Beta
- -0.52
- Avg Volume
- 129.23K
Get TickerSpark's AI analysis on APUS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 24 | Inscobee Inc. | other | 0 |
| Nov 11, 25 | Weintraub Bennett | other | 10,000 |
| Nov 11, 25 | Yoon Hankil | other | 10,000 |
| Nov 11, 25 | Koo Jakap | other | 10,000 |
| Nov 11, 25 | O'DONNELL CAROL A | other | 10,000 |
| Nov 11, 25 | Kogan Elona | other | 10,000 |
| Oct 15, 25 | Kogan Elona | other | 3,000 |
| Oct 15, 25 | O'DONNELL CAROL A | other | 3,000 |
| Oct 15, 25 | Koo Jakap | other | 3,000 |
| Oct 15, 25 | Weintraub Bennett | other | 3,000 |
Our APUS Coverage
We haven't published any research on APUS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APUS Report →